Compare Incyte Corporation (INCY) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs LyondellBasell Industries NV — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while LyondellBasell Industries NV trades at $63.87 (market cap $20.67B). The key difference: Incyte Corporation is the larger of the two by market cap, and LyondellBasell Industries NV pays a 6.44% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | LYB | |
|---|---|---|
Market Cap | $24.54B | $20.67B |
Sector | Health | Basic Materials |
52-Week High | $129.93 | $82.38 |
52-Week Low | $81.61 | $42.28 |
Enterprise Value | $20.04B | $32.26B |
Dividend Yield | — | 6.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
LyondellBasell Industries (LYB) trades at $62.79, up 0.22% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $4.30 versus $3.44 estimated, driven by improved margins from supply disruptions. However, 2025 fundamentals show challenges, including a net loss of $745 million and negative profit margins, though cash flow from operations remains positive at $2.26 billion.
The stock offers potential upside to the $70.56 analyst consensus target, with 46% of analysts rating it a buy, but faces risks from volatile chemical markets and high debt. Investor sentiment is mixed amid earnings recovery signs and macroeconomic pressures on demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
